Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective-Reference-Cited by-同舟云学术

Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective

Published:2017-03 Issue:3 Volume:44 Page:243-250
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Succaria Farah¹,Bhawan Jag¹

Affiliation:

1. Section of Dermatopathology; Department of Dermatology; Boston University School of Medicine; Boston Massachusetts USA

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.13762/fullpdf

Reference47 articles.

1. Cytokines in autoimmune disorders;Feldmann;Int Rev Immunol,1998

2. Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes;Gottlieb;Lupus,2003

3. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy: A study of 16 biopsies;Laga;Am J Dermatopathol,2010

4. A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha demonstrates the Same Class Effect;Shelling;J Clin Aesthet Dermatol,2012

5. Psoriatic skin lesions induced by certolizumab pegol;Klein;Arch Dermatol,2010

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reacciones cutáneas (no paradójicas) inducidas por tratamientos biológicos;Piel;2024-05

2. Methotrexate and electrostimulation cooperate to alleviate the relapse of psoriasiform skin inflammation by suppressing memory T cells;Biochemical Pharmacology;2024-01

3. Methotrexate and sulforaphane loaded PBA-G5-PAMAM dendrimers as a combination therapy for anti-inflammatory response in an intra-articular joint arthritic animal model;International Journal of Pharmaceutics;2023-07

4. Tumor necrosis factor-α inhibitor-related autoimmune disorders;Autoimmunity Reviews;2023-07

5. Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review;Dermatology;2023